The Jackson Laboratory (JAX) in Farmington is working with the M.D. Anderson Cancer Center in Houston to conduct a clinical study of JAX’s new cancer profiling assay, ActionSeq Plus™, in patients with cancers of unknown primary, where cancer cells are found in the body but the place the cancer began is unknown.

Patients eligible for the study will have their tumors’ DNA profile analyzed in the clinical genomics laboratory at JAX. Then, based on tumor DNA sequencing data and a complex gene curation process, JAX will issue a custom report for each patient that MDACC doctors will use to guide individual patient treatment plans.